← All metrics

ApoB: the atherogenic particle count that drives heart disease

Each row is one study of death risk from apob. The bright line is what that study found. The band around it is the range the data still supports — it fades where the evidence thins. Left of the centre line is lower risk.

what the study foundstill plausibleno change
Two groups compared
the whole gap between a high and a low
discordant high apoB / low LDL vs concordant (statin-treated)
Johannesen et al. 2021
21% higher
range 7–36% higher
One step at a time
what each single increase is worth
per 10 mg/dL treated apoB reduction, all lipid-lowering therapies
Khan et al. 2019
5% lower
range 1–8% lower

What it is

Apolipoprotein B (ApoB) counts the number of cholesterol-carrying particles that can lodge in artery walls. It is increasingly viewed as more informative than LDL cholesterol alone.

Why it matters for longevity

The engine is a constructed PCHIP (90 mg/dL = HR 1.0; ≤80 target at 0.95; floor 0.85 at ≤50). No engine paper. Overlay is Sniderman 2011: 12 reports, 233,455 people / 22,950 fatal or nonfatal ischemic CV events; standardized RRR apoB 1.43 (1.35–1.51) vs LDL-C 1.25 vs non-HDL-C 1.34 — heart, not all-cause, and not this knot table. No matching lab-ApoB → ACM dose-response meta opened. Under: ERFC 2009 (IPD 302,430; 1-SD apoB defined as 29 mg/dL; vascular/CHD, not ACM) / Welsh 2019 (1-SD apoB CVD HR 1.23 ≈ LDL 1.20; adding apoB after TC+HDL C-index 0.0004) / Khan 2019 (per 10 mg/dL treated drop, ACM RR 0.95 overall, statins only 0.92; LDL-R–independent MACE 1.02). Marker, not a treatment effect. Engine not moved.

How to improve it

  • Ask your doctor to measure ApoB directly
  • Eat more soluble fiber and plant foods
  • Discuss lipid-lowering therapy if ApoB stays elevated

Evidence, by endpoint

EndpointGradeFinding
—METHOD
PCHIP is constructed (90 = 1.0; target ≤80)
Knots 30/50 = 0.85 floor, 80 = 0.95, 90 = 1.0, 110 = 1.15, 160 = 1.55. No engine paper. Off the 8-metric index — heart, not all-cause. Engine not moved.
Ischemic cardiovascular eventsB
Sniderman is 1.43 ischemic-CV, not ACM
12 reports / 233,455: apoB RRR 1.43 vs LDL 1.25 vs non-HDL 1.34. Fatal or nonfatal ischemic events. No matching lab-ApoB → ACM dose-response meta opened.
All-cause mortality (treated ApoB reduction)A
0.0004 is the increment; 0.95 is treated (Welsh 2019 / Khan 2019)
Welsh: 1-SD apoB CVD 1.23 ≈ LDL 1.20; adding apoB after TC+HDL C-index 0.0004. Khan: per 10 mg/dL treated drop, ACM 0.95 overall, statins only 0.92; LDL-R–independent MACE 1.02. Marker, not every way of moving the number.
MACEB
MR: Benefit Tracks ApoB, Not LDL-C (Ference 2017)
Mendelian randomization using CETP-inhibitor and statin gene scores: a CETP score alone (concordant LDL-C and apoB drop) carried MACE OR 0.946 (0.921–0.972), but combining it with an HMGCR (statin) score — same LDL-C drop, blunted apoB drop — gave MACE OR 0.985 (0.955–1.015), not significant. The cardiovascular benefit tracked the apoB change, not the LDL-C change. MACE, not all-cause mortality.
CHDB
Multivariable MR Favors ApoB Over LDL-C (Richardson 2020)
Multivariable Mendelian randomization (UK Biobank plus CARDIoGRAMplusC4D, 60,801 CHD cases / 123,504 controls): apoB alone carried CHD OR 1.73 (1.56–1.91) per 1-SD. Modeled together with LDL-C and triglycerides, only apoB retained an effect (OR 1.92, 95% CI 1.31–2.81); LDL-C’s association reversed to OR 0.85 (0.57–1.27). CHD, not all-cause mortality.
New-onset ASCVDB
Other Lipids Vanish Once ApoB Is In the Model (Sniderman 2024)
UK Biobank cohort of 293,876 adults free of CVD, 19,982 new-onset ASCVD events over median 11 years: residual apoB risk after accounting for LDL-C and HDL-C carried HR 1.06 (1.04–1.07), while the residual associations of LDL-C, non-HDL-C, and triglycerides disappeared once apoB was in the model. New-onset ASCVD, not all-cause mortality.
All-cause mortalityC
High ApoB, Low LDL Still Raises Death (Johannesen 2021)
Copenhagen cohort of 13,015 statin-treated adults, median 8 years: those with discordantly high apoB and low LDL-C carried ACM HR 1.21 (1.07–1.36) and MI HR 1.49 (1.15–1.92), while high LDL-C with low apoB did not raise all-cause mortality. Treated residual risk, not the untreated apoB value this calculator’s slider represents.
MACE and CADB
Discordance Tracks ApoB Over LDL Particle Count (Epstein 2025)
UK Biobank cohort of 41,099 adults (9,663 MACE, 1,754 CAD events): when apoB and LDL particle number (LDL-P) disagreed, risk tracked apoB. At 2% apoB-above-LDL-P, MACE and CAD carried HR 1.1; at 30% apoB-above-LDL-P, MACE rose to HR 1.4 and CAD to HR 2.5. MACE and CAD, not all-cause mortality.

What argues against this

Welsh et al. 2019 (UK Biobank, 346,686 people) is the strongest opposing source: apoB's 1-SD cardiovascular HR (1.23) was nearly identical to directly measured LDL-C's (1.20), and adding apoB on top of total cholesterol plus HDL improved prediction by only 0.0004 in the C-index — the authors concluded nonfasted TC+HDL is 'sufficient' and apolipoproteins add no meaningful incremental value. This undercuts the case that apoB is a meaningfully superior marker rather than a redundant one, though it does not dispute that apoB tracks cardiovascular risk at all.

Last reviewed 2 September 2026

Evidence

  1. Sniderman et al. (2011) — Circulation: Cardiovascular Quality and Outcomes
    A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk
    View source
  2. Emerging Risk Factors Collaboration (Di Angelantonio et al.) (2009) — JAMA
    Major lipids, apolipoproteins, and risk of vascular disease
    View source
  3. Welsh et al. (2019) — Circulation
    Comparison of Conventional Lipoprotein Tests and Apolipoproteins in the Prediction of Cardiovascular Disease
    View source
  4. Khan et al. (2019) — European Journal of Preventive Cardiology
    Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: Systematic review and meta-analysis of trials
    View source
  5. Ference et al. (2017) — JAMA
    Association of Genetic Variants Related to CETP Inhibitors and Statins With Lipoprotein Levels and Cardiovascular Risk
    View source
  6. Richardson et al. (2020) — PLoS Medicine
    Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysis
    View source
  7. Sniderman et al. (2024) — European Heart Journal
    Discordance among apoB, non-high-density lipoprotein cholesterol, and triglycerides: implications for cardiovascular prevention
    View source
  8. Walldius et al. (AMORIS study) (2001) — The Lancet
    High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study)
    View source
  9. Johannesen et al. (2021) — Journal of the American College of Cardiology
    Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients
    View source
  10. Johannesen et al. (2024) — Journal of the American College of Cardiology
    Excess Apolipoprotein B and Cardiovascular Risk in Women and Men
    View source
  11. Epstein et al. (2025) — European Journal of Preventive Cardiology
    Apolipoprotein B outperforms low density lipoprotein particle number as a marker of cardiovascular risk in the UK Biobank
    View source
See how apob fits your full score
See how it fits the 8-metric index in the calculator.
Open calculator

Educational content only — not medical advice, diagnosis, or treatment. Not a medical device; not FDA evaluated. Consult a qualified healthcare professional about your own health, and call emergency services for urgent symptoms. Full medical disclaimer →